These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32519208)

  • 21. Psychosocial functioning as a mediator between childhood trauma and symptom severity in patients with schizophrenia.
    Neumann E; Rixe J; Driessen M; Juckel G
    Child Abuse Negl; 2023 Oct; 144():106372. PubMed ID: 37499307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between symptom control and functional improvement in patients with acute schizophrenia: A post hoc analysis of an open-label, single-arm, multi-center study of paliperidone-extended release formulation.
    Si TM; Zhang YL; Feng Y; Zhuo JM; Cai S; Zhang L
    Psychiatry Res; 2019 Apr; 274():301-305. PubMed ID: 30831454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
    Swartz MS; Perkins DO; Stroup TS; Davis SM; Capuano G; Rosenheck RA; Reimherr F; McGee MF; Keefe RS; McEvoy JP; Hsiao JK; Lieberman JA;
    Am J Psychiatry; 2007 Mar; 164(3):428-36. PubMed ID: 17329467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
    Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
    Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
    Tollefson GD; Andersen SW
    J Clin Psychiatry; 1999; 60 Suppl 5():23-9; discussion 30. PubMed ID: 10192404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of Antipsychotic Drugs for 24-Month Maintenance Treatment in First-Episode Schizophrenia: Evidence From a Community-Based "Real-World" Study.
    Zhang C; Chen MJ; Wu GJ; Wang ZW; Rao SZ; Zhang Y; Yi ZH; Yang WM; Gao KM; Song LS
    J Clin Psychiatry; 2016 Nov; 77(11):e1460-e1466. PubMed ID: 28076667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of antipsychotic medications on quality of life and psychosocial functioning in patients with early-stage schizophrenia: 1-year follow-up naturalistic study.
    Guo X; Zhang Z; Zhai J; Fang M; Hu M; Wu R; Liu Z; Zhao J;
    Compr Psychiatry; 2012 Oct; 53(7):1006-12. PubMed ID: 22516246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Social and functional outcomes with two doses of aripiprazole lauroxil vs placebo in patients with schizophrenia: a post-hoc analysis of a 12-week phase 3 efficacy study.
    Correll CU; Stanford AD; Claxton A; Du Y; Weiden PJ
    Psychiatry Res; 2019 Apr; 274():176-181. PubMed ID: 30802689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine.
    Voruganti LP; Awad AG; Parker G; Forrest C; Usmani Y; Fernando ML; Senthilal S
    Schizophr Res; 2007 Nov; 96(1-3):146-55. PubMed ID: 17728106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia.
    Kim SW; Yoon JS; Kim YS; Ahn YM; Kim CE; Go HJ; Chee IS; Jung SW; Chung YC; Kim YD; Joe S; Lee J; Kwon YJ; Yoon BH; Jae YM
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Aug; 38(2):228-35. PubMed ID: 22516251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia.
    Weiss EM; Bilder RM; Fleischhacker WW
    Psychopharmacology (Berl); 2002 Jun; 162(1):11-7. PubMed ID: 12107611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The subjective quality of life of patients with schizophrenia: influence of psychopathology and patients' expectations. A comparative study].
    Salomé F; Petitjean F; Germain C; Demant JC
    Encephale; 2004; 30(1):60-8. PubMed ID: 15029078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia.
    Nasrallah H; Morosini P; Gagnon DD
    Psychiatry Res; 2008 Nov; 161(2):213-24. PubMed ID: 18848731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
    Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
    Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment effectiveness in patients with schizophrenia as measured by the ASSESS battery - first longitudinal data.
    Ladea M; Barbu CM; Juckel G
    Psychiatr Danub; 2015 Dec; 27(4):364-70. PubMed ID: 26609648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relative contribution of antipsychotics, negative symptoms and executive functions to social functioning in stable schizophrenia.
    Rocca P; Montemagni C; Castagna F; Giugiario M; Scalese M; Bogetto F
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):373-9. PubMed ID: 19211031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of paliperidone extended release on functioning level and symptoms of patients with recent onset schizophrenia: An open-label, single-arm, flexible-dose, 12-months follow-up study.
    Üçok A; Saka MC; Bilici M
    Nord J Psychiatry; 2015 Aug; 69(6):426-32. PubMed ID: 25549697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is personal and social functioning associated with subjective quality of life in schizophrenia patients living in the community?
    Brissos S; Balanzá-Martinez V; Dias VV; Carita AI; Figueira ML
    Eur Arch Psychiatry Clin Neurosci; 2011 Oct; 261(7):509-17. PubMed ID: 21384166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Subjective assessments of the quality of life, well-being and self-efficacy in patients with schizophrenia.
    Chino B; Nemoto T; Fujii C; Mizuno M
    Psychiatry Clin Neurosci; 2009 Aug; 63(4):521-8. PubMed ID: 19531107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Social functioning and quality of life in the schizophrenic patient: advantages of amisulpride.
    Saleem P; Olié JP; Loo H
    Int Clin Psychopharmacol; 2002 Jan; 17(1):1-8. PubMed ID: 11806403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.